Patrick Piliè, MD, discusses the benefit of second-generation androgen receptor inhibitors in patients with nonmetastatic castration-resistant prostate cancer.
Patrick Piliè, MD, an assistant professor in the Department of Genitourinary Medical Oncology of the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center, discusses the benefit of second-generation androgen receptor (AR) inhibitors in patients with nonmetastatic castration-resistant prostate cancer (CRPC).
Currently, 3 large randomized, phase 3 trials examined the use of second-generation AR inhibitors in patients with nonmetastatic CRPC, according to Piliè. Specifically, the ARAMIS (NCT02200614), PROSPER (NCT02003924), and SPARTAN (NCT01946204) trials, examined darolutamide (Nubeqa), enzalutamide (Xtandi), and apalutamide (Erleada), respectively, Piliè says.
All 3 trials met their primary end point of metastasis-free survival and demonstrated an improvement in overall survival (OS), Piliè notes. In particular, the OS benefit achieved with darolutamide plus androgen deprivation therapy (ADT) translated to a 31% reduction in risk of death compared with ADT alone, Piliè concludes.